TARS
Tarsus Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$78.09
−1.19%Next report
Analyst consensus
- Next report date
- Nov 3, 2026
- EPS estimate
- -$1.43
- Revenue estimate
- $183.7M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.43
- EPS estimate
- -$0.19
- Revenue actual
- $173.9M
- Revenue estimate
- $169.7M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- -13.2%
- Revenue beats (12Q)
- 6
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $96
- PT range
- $88 – $105
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.19 | -$0.43 | Miss -124.23% | $173.9M |
| May 6, 2026 | -$0.40 | -$0.16 | Beat 60.17% | $162.1M |
| Feb 23, 2026 | -$0.19 | -$0.20 | Miss -3.00% | $151.7M |
| Nov 4, 2025 | -$0.35 | -$0.30 | Beat 14.29% | $118.7M |
| Aug 6, 2025 | -$0.33 | -$0.48 | Miss -45.45% | $102.7M |
| May 1, 2025 | -$0.69 | -$0.64 | Beat 7.25% | $78.3M |
| Aug 8, 2024 | -$0.98 | -$0.88 | Beat 10.20% | $40.8M |
| Feb 27, 2024 | -$1.37 | -$1.31 | Beat 4.38% | $13.1M |
| Nov 9, 2023 | -$1.40 | -$1.28 | Beat 8.57% | $1.9M |
| Aug 10, 2023 | -$1.08 | -$1.17 | Miss -8.33% | $15.3M |
| Mar 13, 2023 | -$0.97 | -$0.49 | Beat 49.48% | $10.0M |
| Nov 9, 2022 | -$0.98 | -$0.84 | Beat 14.29% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 3, 2026